Functional bowel disorders, including irritable bowel syndrome (IBS), are common disorders that have a significant impact on patients' quality of life. These disorders present major challenges to healthcare providers, as few effective medical therapies are currently available. Recently, there has been increasing interest in dietary therapies for IBS, particularly a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs). Since ingestion of FODMAPs increases the delivery of readily fermentable substrates and water to the distal small intestine and colon-which results in luminal distention and gas-the reduction of FODMAPs in a patient's diet may improve functional gastrointestinal symptoms. This paper will review the pathophysiology of IBS and the role of FODMAPs for the treatment of this condition.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966170 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Editorial: Alpha-Delta Ligands in Irritable Bowel Syndrome.
Aliment Pharmacol Ther
January 2025
Vatche and Tamar Manoukian Division of Digestive Diseases, The University of California Los Angeles, California, Los Angeles, USA.
The Impact of Hangeshashinto on Symptoms and Gut Microbiota in Diarrhea-type Irritable Bowel Syndrome: A Retrospective Analysis.
J Anus Rectum Colon
January 2025
Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.
Objectives: Effective treatments for diarrhea-type irritable bowel syndrome (IBS-D) are limited. Hangeshashinto (HST), an anti-inflammatory Kampo medicine, may offer benefits but its efficacy for IBS-D requires further investigation. This study evaluated IBS-D symptom improvement and gut microbiota changes following HST administration.
View Article and Find Full Text PDFAcute stress triggers sex-dependent rapid alterations in the human small intestine microbiota composition.
Front Microbiol
January 2025
Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Background/aims: Digestive disorders of gut-brain interaction (DGBI) are very common, predominant in females, and usually associated with intestinal barrier dysfunction, dysbiosis, and stress. We previously found that females have increased susceptibility to intestinal barrier dysfunction in response to acute stress. However, whether this is associated with changes in the small bowel microbiota remains unknown.
View Article and Find Full Text PDFExploring Manual Therapy in the Management of Irritable Bowel Syndrome in Adults: A Scoping Review.
Complement Ther Med
January 2025
Department of Psychosocial Rehabilitation, Medical University of Lodz, Poland, Narutowicza 60, 90-136 Lodz, Poland.
Introduction: IBS is a prevalent gut-brain interaction disorder characterized by abdominal pain and altered bowel habits, significantly affecting quality of life (QoL). IBS contributes to substantial work absenteeism and economic burdens and often coexists with other somatic and psychiatric conditions, with psychological well-being being a critical determinant of QoL. IBS sufferers often turn to MT due to dissatisfaction with conventional treatments.
View Article and Find Full Text PDFHuman-derived microRNA 21 regulates indole and L-tryptophan biosynthesis transcripts in the gut commensal .
mBio
January 2025
Centre for Microbiology and Environmental Systems Science, Department of Microbiology and Ecosystem Science, Division of Microbial Ecology, University of Vienna, Vienna, Austria.
Unlabelled: In the gut, microRNAs (miRNAs) produced by intestinal epithelial cells are secreted into the lumen and can shape the composition and function of the gut microbiome. Crosstalk between gut microbes and the host plays a key role in irritable bowel syndrome (IBS) and inflammatory bowel diseases, yet little is known about how the miRNA-gut microbiome axis contributes to the pathogenesis of these conditions. Here, we investigate the ability of miR-21, a miRNA that we found decreased in fecal samples from IBS patients, to associate with and regulate gut microbiome function.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!